Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rare molecular subtypes of lung cancer
Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 229-249
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Lung cancer in patients who have never smoked — an emerging disease
Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 121-146
Open Access | Times Cited: 69
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Yuchu Xiang, Xudong Liu, Yifan Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 23
Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma
Long Zhang, Yajun Xiong, Jie Zhang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
Paul Hofman, Sabina Berezowska, Daniel Kazdal, et al.
Virchows Archiv (2023) Vol. 484, Iss. 2, pp. 233-246
Open Access | Times Cited: 20
Targeted therapeutic options in early and metastatic NSCLC-overview
Gabriella Gálffy, Éva Morócz, Réka Korompay, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 6
A review of obstructive sleep apnea and lung cancer: epidemiology, pathogenesis, and therapeutic options
Yuan Fang, Yanxia Hu, Fei Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Unravelling the diagnostic pathology and molecular biomarkers in lung cancer
Andriani Charpidou, Georgia Hardavella, Efimia Boutsikou, et al.
Breathe (2024) Vol. 20, Iss. 2, pp. 230192-230192
Open Access | Times Cited: 4
Genomic Testing in Brazil: Navigating Challenges and Harnessing Opportunities for Global Health Impact
Guilherme Harada, Tiago Biachi De Castria, Fábio Ynoe de Moraes
JCO Global Oncology (2025), Iss. 11
Open Access
Identification of KRT16 and ANXA10 as cell cycle regulation genes for lung adenocarcinoma based on self-transcriptome sequencing of surgical samples and TCGA public data mining
Wenjian Liu, Jianzhong Shen, Renquan Zhang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers
Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist
Paul Hofman, Iordanis Ourailidis, Eva Romanovsky, et al.
Lung Cancer (2025) Vol. 200, pp. 108110-108110
Closed Access
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
Zhaohui Arter, Kevin Shieh, Misako Nagasaka, et al.
Lung Cancer Targets and Therapy (2025) Vol. Volume 16, pp. 1-9
Open Access
circZNF707 promoted glycolysis and tumor progression through miR-668-3p-PFKM axis in NSCLC
Wei Chen, Shuai Fang, Xianqiao Wu, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
Martin Sattler, Ravi Salgia
Cell Reports Medicine (2025), pp. 101983-101983
Open Access
From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC
Hongyu Liu
Highlights in Science Engineering and Technology (2025) Vol. 129, pp. 194-201
Closed Access
The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC
Misako Nagasaka, Upal Roy, Alexandra Berk, et al.
Future Oncology (2025), pp. 1-7
Closed Access
NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer
Zhouwenli Meng, Jian Li, Hui Wang, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
RAF1‐rearranged spindle cell neoplasm: a clinicopathological and molecular genetic study of six cases with review of the literature
Peipei Zhu, Xuewei Zeng, Linjie Yang, et al.
Histopathology (2025)
Closed Access
Cancers du poumon avec addictions rares : RET, ROS-1, MET, HER2 et BRAF
Clara Morin, Julien Mazières
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S117-3S126
Closed Access
Identifying the Intergenic ALK Fusion LOC388942‐ALK as a Driver of Non–Small Cell Lung Cancer
Xiaoqian Zhai, Manli Wang, Qi Zhang, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Development and Preclinical Evaluation of a Gallium-68 Labeled Novel Diagnostic Tracer for Visualizing ALK Expression in Tumor
Zhenpeng Yu, Kexin Sun, Dan Zhang, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107087-107087
Open Access
Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
Antoine Desîlets, Matteo Repetto, Soo‐Ryum Yang, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
Molekularpathologie des nichtkleinzelligen Lungenkarzinoms: aktuelle und kommende Biomarker
Helen Pasternack, Jutta Kirfel
Deleted Journal (2025)
Open Access
Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights
Guanbin Huang, Tongtong Xia, Dongxiao Yang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis
Rafael Parra‐Medina, Juan Pablo Castañeda-González, Luisa Montoya, et al.
Lung Cancer (2023) Vol. 185, pp. 107378-107378
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top